Aditxt, Inc.
ADTX evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Market Cap:
- $3.0M
What it means
What to watch
Prepared research question
What matters most for ADTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADTX
Aditxt, Inc. (ADTX) is a Nasdaq-listed holding company that operates a platform model to acquire, build, and commercialize life-science innovations across autoimmune, oncology, women's health, and infectious disease subsidiaries, but faces severe financial distress with no revenue and negative shareholders' equity as of March 31, 2026.
Key risk: Cash runway insufficient
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$3.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Aditxt, Inc. (ADTX) is a Nasdaq-listed holding company that operates a platform model to acquire, build, and commercialize life-science innovations across autoimmune, oncology, women's health, and infectious disease subsidiaries, but faces severe financial distress with no revenue and negative shareholders' equity as of March 31, 2026.
- Aditxt is a Nasdaq-listed public company with subsidiaries including Adimune (autoimmune), Pearsanta (cancer detection), Adifem (women's health), and Adivir (infectious disease) [sec · filed 2025-12-16].
- As of March 31, 2026, the company reported total revenue of $0.0M, net income of -$15.9M, and shareholders' equity of -$33.3M [sec].
- The company had an accumulated deficit of $181,061,686 as of June 30, 2025 [sec_mda · as of 2025-08-14].
- Management states that remaining funds will not be sufficient to fund operations for the next 12 months, creating substantial doubt about the ability to continue as a going concern beyond one year [sec_mda · as of 2026-05-20].
- The company is over 90 days past due on a significant number of vendor obligations as of March 31, 2026 [sec_mda · as of 2026-05-20].
What works
- Aditxt has built a diversified portfolio of subsidiaries spanning multiple therapeutic and diagnostic areas, including autoimmune, cancer detection, women's health, and infectious disease [sec · filed 2025-12-16].
- The company's platform model is designed to acquire, build, and commercialize high-potential innovations with global impact potential [sec · filed 2025-12-16].
- Aditxt has a broad and growing shareholder base as a Nasdaq-listed public company [sec · filed 2025-12-16].
What to weigh
- The company has no revenue ($0.0M) and negative shareholders' equity (-$33.3M) as of March 31, 2026 [sec].
- Management states that remaining funds will not be sufficient to fund operations for the next 12 months, creating substantial doubt about the ability to continue as a going concern beyond one year [sec_mda · as of 2026-05-20].
- The company is over 90 days past due on a significant number of vendor obligations as of March 31, 2026 [sec_mda · as of 2026-05-20].
- The company has incurred substantial operating losses since inception and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2025-08-14].
From the filings
Quoted directly from source documents.
Aditxt's diversified subsidiary portfolio
“Aditxt is a Nasdaq-listed public company with a broad and growing shareholder base and a diversified portfolio of subsidiaries spanning multiple therapeutic and diagnostic areas. These include: | | ● | Adimune - developing a therapeutic platform designed to reprogram the immune system to address autoimmune diseases; | | --- | --- | --- | | | ● | Pearsanta - advancing early cancer and disease detection technologies; | | --- | --- | --- | | | ● | Adifem - targeting women's health innovations; and | | --- | --- | --- |”
SEC filings · December 16, 2025
Going concern doubt and insufficient funds
“We believe our remaining funds on hand will not be sufficient to fund our operations for the next 12 months and such creates substantial doubt about our ability to continue as a going concern beyond one year.”
SEC MD&A · May 20, 2026
Vendor payment delinquency
“We are currently over 90 days past due on a significant number of vendor obligations.”
SEC MD&A · May 20, 2026
Accumulated deficit
“As of June 30, 2025, we had an accumulated deficit of $181,061,686.”
SEC MD&A · August 14, 2025
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Remaining funds will not sustain operations for 12 months; substantial doubt about going concern [sec_mda · as of 2026-05-20].
- No revenue generation — Total revenue of $0.0M as of March 31, 2026; no commercial product sales [sec].
- Negative equity and losses — Shareholders' equity -$33.3M and net income -$15.9M as of March 31, 2026 [sec].
- Vendor payment delinquency — Over 90 days past due on significant vendor obligations as of March 31, 2026 [sec_mda · as of 2026-05-20].
What to watch
- Ability to raise additional capital through equity, debt, or partnerships to fund operations and clinical trials [sec_mda · as of 2026-05-20].
- Progress of subsidiaries (Adimune, Pearsanta, Adifem, Adivir) toward clinical and commercial milestones [sec · filed 2025-12-16].
- Outcome of the Cellvera acquisition attempt and impact on antiviral portfolio strategy [sec_mda · as of 2025-08-14].
- Any regulatory or clinical developments for the company's therapeutic platforms [sec_mda · as of 2026-03-31].
Sources: Competitor trials · SEC filings · SEC MD&A · Generated September 29, 2026 · How we verify sources →
Run Aditxt, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aditxt, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
OCF -$5M · Net income -$16M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
12 buys · 12 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$20K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 11,721 | $11K |
| morgan stanley | 8,002 | $8K |
| tower research capital llc (trc) | 547 | $535 |
| danske bank a/s | 3 | $3 |
| group one trading llc | 2 | $2 |
| ifp advisors, inc | 1 | $1 |
| ubs group ag | 1 | $1 |
| western wealth management, llc | 1 | $1 |
| darwin wealth management, llc | 1 | $0 |
| osaic holdings, inc. | 2 | $0 |
Short Interest
as of May 20, 2026- % of float
- 27.0%
- Days to cover
- 0.1
- Shares short
- 9,058
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aditxt, Inc.?
Aditxt, Inc. (ADTX) is a Nasdaq-listed holding company that operates a platform model to acquire, build, and commercialize life-science innovations across autoimmune, oncology, women's health, and infectious disease subsidiaries, but faces severe financial distress with no revenue and negative shareholders' equity as of March 31, 2026.
Who is the CEO of Aditxt, Inc.?
Mr. Jeffrey M. Busch J.D. is the chief executive officer of Aditxt, Inc. (ADTX).
Where is Aditxt, Inc. headquartered?
Aditxt, Inc. (ADTX) is headquartered in Mountain View, CA, United States.
What therapeutic areas does Aditxt, Inc. focus on?
Aditxt, Inc. develops therapies across Oncology, Immunology, Metabolic, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.